Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ERAS 601

Next Previous
Drug Profile

ERAS 601

Alternative Names: ERAS-601

Latest Information Update: 14 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NiKang Therapeutics
  • Developer Erasca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 14 Jul 2024 Phase I trial is still ongoing for Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Australia (PO)(NCT04670679)
  • 31 May 2024 Efficacy and adverse events data from phase I/Ib FLAGSHP-1 trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top